(RTTNews) - Eli Lilly and Company (LLY) reported topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed - with or without pembrolizumab - as an initial treatment for patients with rearranged during transfection fusion-positive advanced or metastatic non-small cell lung cancer. The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival.
The company will present full results from the LIBRETTO-431 trial at an upcoming medical meeting, submitted to a peer-reviewed journal, and discussed with health authorities.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
